Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-05-04
Based on 637 first isolates · URO · Cystitis (lower UTI) · 2024-05-05 → 2025-05-04
Urology
Per-organism detail: URO urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 84 % (80 %–86 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (6 %), Klebsiella pneumoniae (5 %), Pseudomonas aeruginosa (5 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
85 %
76 %
n = 42
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
84 %
88 %
n = 42
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
80 %
71 %
n = 42
ciprofloxacin CIP
trend · Escherichia coli
77 %
76 %
n = 42
mecillinam MEC
trend · Escherichia coli lower UTI only
76 %
67 %
n = 42
ceftriaxone CRO
trend · Escherichia coli
76 %
69 %
n = 42
trimethoprim TMP
trend · Escherichia coli lower UTI only
70 %
62 %
n = 42
69 %
60 %
n = 42
47 %
50 %
n = 42
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
12 %
19 %
n = 42
4 %
5 %
n = 42
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
5 %
n = 42

Most likely organisms for this profile

Escherichia coli
58 %
Klebsiella pneumoniae
11 %
Enterococcus faecalis
9 %
Proteus mirabilis
6 %
Pseudomonas aeruginosa
5 %
Staphylococcus saprophyticus
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.